Robert Weingarten - Lixte Biotechnology VP CFO
| LIXTW Stock | USD 0.02 0.01 26.43% |
Insider
Robert Weingarten is VP CFO of Lixte Biotechnology Holdings
| Age | 72 |
| Address | 680 East Colorado Boulevard, Pasadena, CA, United States, 91101 |
| Phone | 631 830 7092 |
| Web | https://lixte.com |
Robert Weingarten Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robert Weingarten against Lixte Biotechnology stock is an integral part of due diligence when investing in Lixte Biotechnology. Robert Weingarten insider activity provides valuable insight into whether Lixte Biotechnology is net buyers or sellers over its current business cycle. Note, Lixte Biotechnology insiders must abide by specific rules, including filing SEC forms every time they buy or sell Lixte Biotechnology'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert Weingarten over six months ago Acquisition by Robert Weingarten of 200000 shares of Lixte Biotechnology subject to Rule 16b-3 |
Lixte Biotechnology Management Efficiency
The company has return on total asset (ROA) of (0.8733) % which means that it has lost $0.8733 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.6333) %, meaning that it generated substantial loss on money invested by shareholders. Lixte Biotechnology's management efficiency ratios could be used to measure how well Lixte Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.24 in 2024. Return On Capital Employed is likely to drop to -1.34 in 2024. Non Currrent Assets Other is likely to climb to about 100 K in 2024, whereas Total Assets are likely to drop slightly above 2.2 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Edward Calamai | DiaMedica Therapeutics | N/A | |
| Joshua MBA | Centessa Pharmaceuticals PLC | 50 | |
| David Grainger | Centessa Pharmaceuticals PLC | 55 | |
| Karen Anderson | Centessa Pharmaceuticals PLC | 56 | |
| Saurabh MD | Centessa Pharmaceuticals PLC | 48 | |
| Dominic Cundari | DiaMedica Therapeutics | 73 | |
| Iqbal LLB | Centessa Pharmaceuticals PLC | 43 | |
| Tia Bush | Centessa Pharmaceuticals PLC | 53 | |
| Thomas Templeman | Centessa Pharmaceuticals PLC | 64 | |
| MBA MD | Centessa Pharmaceuticals PLC | 51 | |
| Donald MBA | Lyra Therapeutics | 70 | |
| Scott CA | DiaMedica Therapeutics | 59 | |
| MD MSc | Centessa Pharmaceuticals PLC | 64 | |
| Jason Cavalier | Lyra Therapeutics | 51 | |
| Dr Roberts | Lyra Therapeutics | 56 | |
| David Chao | Centessa Pharmaceuticals PLC | 56 | |
Management Performance
| Return On Equity | -1.63 | ||||
| Return On Asset | -0.87 |
Lixte Biotechnology Leadership Team
Elected by the shareholders, the Lixte Biotechnology's board of directors comprises two types of representatives: Lixte Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lixte. The board's role is to monitor Lixte Biotechnology's management team and ensure that shareholders' interests are well served. Lixte Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lixte Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Kovach, Chairman, Founder | ||
| Esq JD, Consultant | ||
| Bastiaan MSc, CEO President | ||
| Johannes MD, Chief Officer | ||
| James MD, Chief Officer | ||
| Robert Weingarten, VP CFO | ||
| Eric JD, Chief Officer | ||
| Francis Johnson, Consultant |
Lixte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lixte Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.63 | ||||
| Return On Asset | -0.87 | ||||
| Number Of Shares Shorted | 6.04 K | ||||
| EBITDA | 3.21 K | ||||
| Net Income | (5.09 M) | ||||
| Cash And Equivalents | 1.08 M | ||||
| Cash Per Share | 0.10 X | ||||
| Total Debt | 313.86 K | ||||
| Current Ratio | 5.36 X | ||||
| Book Value Per Share | 0.22 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.